

REPORT

Patient Name	: Mrs. GURVIR KAUR	Reg. No.	: 00152101060167
Age and Sex	: 56 Yrs / Female	PCC Code	: PCL-HR-216
Referring Doctor	: NA	Sample Drawn Date	: 05-Jan-2021 04:15 AM
Referring Customer	:	Registration Date	: 07-Jan-2021 09:25 AM
Vial ID	: J0303604	Report Date	: 12-Jan-2021 03:35 PM
Sample Type	: Serum	Report Status	: Final Report
Client Address	: 6349/1, Nicholson Road, Ambala Cantt		

CLINICAL BIOCHEMISTRY

Test Name	Obtained Value	Units	Bio. Ref. Intervals (Age/Gender specific)	Method
*Cyfra 21- 1 Lung cancer marker	4.67	ng/mL	<3.30	ECLIA

Comments:

- This test is not recommended for the primary diagnosis of Lung cancer. In diagnosed cases of NSCLC, post treatment baseline samples should be followed by serial determinations at monthly intervals for assessing prognosis. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose. Levels greater than 30 ng/mL are highly indicative of Primary Bronchial Carcinoma.

Clinical Use: Monitoring the course of Non-Small Cell Lung Cancer (NSCLC) Course monitoring in Myoinvasive Bladder Cancer.

Increased Levels: Non-Small Cell Carcinoma Lung, Acute Pneumonia, Tuberculosis, Interstitial Lung Disease, Liver Cirrhosis, Renal Failure.

Correlate Clinically.

Result rechecked and verified for abnormal cases.

*** End Of Report ***



DR. PRATAP PATIL
MD PATHOLOGY